Examkin

Soru

Zorluk: ZorPharmacologic Interventions

A 72-year-old man is admitted to the inpatient medical ward for severe, poorly controlled lower back and pelvic pain secondary to metastatic prostate cancer. He reports that the pain has progressively worsened over the past two weeks and is now 9/10 in intensity. His current pain regimen consists of oral acetaminophen and oral ibuprofen, which currently provide minimal relief. His medical history is significant for hypertension, major depressive disorder, and chronic kidney disease stage 4 (baseline estimated glomerular filtration rate is 22 mL/min/1.73 m²). Current daily medications include amlodipine, sertraline, acetaminophen, and ibuprofen. Vital signs are temperature 37.1°C (98.8°F), blood pressure 152/88 mm Hg, pulse 98/min, and respirations 18/min. Physical examination reveals exquisite tenderness to palpation over the lumbar spine and posterior pelvis. The patient is awake, alert, and expresses a strong desire for immediate pain relief. The attending physician plans to discontinue the ibuprofen and initiate a strong opioid. Which of the following is the most appropriate pharmacologic intervention for this patient's pain?

  1. Intravenous fentanyl via patient-controlled analgesiaCevap
  2. B
    Intravenous morphine via patient-controlled analgesia
  3. C
    Transdermal fentanyl patch
  4. D
    Intravenous ketorolac on a scheduled basis
  5. E
    Oral tramadol on a scheduled basis

Cevap

Intravenous fentanyl via patient-controlled analgesia
Intravenous fentanyl via patient-controlled analgesia is the safest and most effective choice for this patient. Fentanyl undergoes hepatic metabolism into inactive metabolites, making it an ideal opioid for patients with advanced chronic kidney disease (CKD) or end-stage renal disease, as there is no risk of toxic metabolite accumulation. Furthermore, because the patient is in a state of acute, severe pain crisis, the intravenous route allows for rapid dose titration and immediate analgesic effect.

Adım Adım Çözüm

1
Identify the primary clinical objective and acuity.
The patient requires immediate relief for severe (9/10), acute-on-chronic cancer pain.
This establishes the need for a rapid-acting, potent analgesic route (e.g., intravenous rather than transdermal).
2
Analyze the patient's comorbidities that restrict pharmacologic choices.
The patient has stage 4 chronic kidney disease (eGFR 22 mL/min/1.73 m²).
Renal impairment dictates which opioids and analgesics are safe, as some produce toxic metabolites that rely on renal clearance.
3
Review the patient's current medication list for potential drug-drug interactions.
The patient is taking sertraline, a selective serotonin reuptake inhibitor (SSRI).
Adding medications with serotonergic activity (like tramadol or meperidine) increases the risk of serotonin syndrome.
4
Select the most appropriate analgesic and route based on the established constraints.
Intravenous fentanyl is selected.
Fentanyl lacks active metabolites (making it safe in CKD), does not interact with SSRIs, and the IV PCA route provides the rapid onset necessary for acute pain stabilization.

Anahtar Kavram

In patients with advanced chronic kidney disease, opioids that lack active, renally cleared metabolites (such as fentanyl and methadone) are preferred. Morphine should be avoided due to the accumulation of neurotoxic metabolites.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru